Stay updated on Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.

Latest updates to the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor metadata update with no changes to study information.SummaryDifference0.1%

- Check13 days agoChange DetectedAdds explicit institution names (Moffitt Cancer Center and Research Institute) and a 'Helpful Links Provided by' section to the study page, clarifying sponsorship and related resources.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedDeleted footer elements include the Moffitt sponsor attribution and the Helpful Links section. This reduces visibility of institutional affiliation and access to related resources on the study page.SummaryDifference0.2%

- Check34 days agoChange DetectedRevision: v3.4.2 was added and the previous funding-status notice (Revision: v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedA government funding notice has been added to the page, and the revision version updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check48 days agoChange DetectedThe page now displays a glossary toggle and introduces a new 'Last Update Submitted that Met QC Criteria' timestamp, along with 'No FEAR Act Data' and a new revision label 'v3.4.0'. The previously shown items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' have been removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.